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Abstract
Background: Sequencing of the human genome has identified numerous chromosome copy number additions and 
subtractions that include stable partial gene duplications and pseudogenes that when not properly annotated can 
interfere with genetic analysis. As an example of this problem, an evolutionary chromosome event in the primate 
ancestral chromosome 18 produced a partial duplication and inversion of rho-associated protein kinase 1 (ROCK1 -
18q11.1, 33 exons) in the subtelomeric region of the p arm of chromosome 18 detectable only in humans. ROCK1 and 
the partial gene copy, which the gene databases also currently call ROCK1, include non-unique single nucleotide 
polymorphisms (SNPs).
Results: Here, we characterize this partial gene copy of the human ROCK1, termed Little ROCK, located at 18p11.32. 
Little ROCK includes five exons, four of which share 99% identity with the terminal four exons of ROCK1 and one of 
which is unique to Little ROCK. In human while ROCK1 is expressed in many organs, Little ROCK expression is restricted to 
vascular smooth muscle cell (VSMC) lines and organs rich in smooth muscle. The single nucleotide polymorphism 
database (dbSNP) lists multiple variants contained in the region shared by ROCK1 and Little ROCK. Using gene and 
cDNA sequence analysis we clarified the origins of two non-synonymous SNPs annotated in the genome to actually be 
fixed differences between the ROCK1 and the Little ROCK gene sequences. Two additional coding SNPs were valid 
polymorphisms selectively within Little ROCK. Little ROCK-Green Fluorescent fusion proteins were highly unstable and 
degraded by the ubiquitin-proteasome system in vitro.
Conclusion: In this report we have characterized Little ROCK (ROCK1P1), a human expressed pseudogene derived from 
partial duplication of ROCK1. The large number of pseudogenes in the human genome creates significant genetic 
diversity. Our findings emphasize the importance of taking into consideration pseudogenes in all candidate gene and 
genome-wide association studies, as well as the need for complete annotation of human pseudogenome.
Background
The ROCK1 and 2 serine/threonine kinases regulate
many cellular responses such as cell growth, proliferation,
and apoptosis through their effects on the cytoskeleton
and microtubule network organization [1,2]. The ROCK1
and ROCK2 proteins share a similar structure character-
ized by an amino terminal coiled-coil domain containing
the kinase activity, a Rho binding site, and a carboxy-ter-
minal pleckstrin homology (PH) domain [3]. Activation
by GTP-bound Rho-A involves displacement of the PH
domain and exposure of the kinase domain to substrate
[4-8]. In vascular smooth muscle cells (VSMC) ROCK1
and 2 activity promotes cellular contraction by direct
phosphorylation of the myosin binding subunit (MBS)
leading to inhibition of myosin light chain phosphatase
activity [9,10]. Activated Rho kinases can also trigger
phosphorylation of MBS through the Zip-like kinase
[11,12] or by phosphorylating the CPI-17 protein, which
physically binds and inhibits the actions of PP1M, the
catalytic subunit of MLCP [13,14]. VSMC contraction
triggered by activation of the ROCK1 and ROCK2 path-
way causes blood vessels to constrict, which increases
blood pressure [15]. Inhibitors of ROCK1 and 2 block
VSMC contraction and lower blood pressure (BP) in
humans [16], block acetylcholine-induced arterial vaso-
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constriction [17], and improve exercise-induced myocar-
dial ischemia [18].
Given the importance of ROCK1 and ROCK2 to BP
and by extension cardiovascular diseases we sought to
understand whether genetic differences in these genes
contribute to the normal variation of blood pressure that
exists in the general population. The ROCK1 and ROCK2
proteins are products of separate genes located on chro-
mosomes 18 and 2, respectively. A ROCK2 gene polymor-
phism located adjacent to the coiled-coiled domain
(ROCK2-T432N) has been associated with BP [19]. At
the start of our study computational analysis of ROCK1
gene revealed that the single nucleotide polymorphism
database (dbSNP) lists several ROCK1 coding region vari-
ants, assigned to two different loci on chromosome 18.
Reported studies designed to determine the genomic dif-
ferences that distinguish the human chromosome 18
from its homolog in great apes (chimpanzee, orangutan,
and gorilla) identified a chromosome 18 pericentric break
causing an inversion and transposition event that
included part of ROCK1 as well as USP14 and THOC1
[20,21]. The result of this chromosomal event, which
occurred at some point before humans evolutionarily
separated from great apes, was the placement of USP14,
THOC1 and a partial duplication of ROCK1 in the sub-
telomeric region of the p arm of chromosome 18 [20,21].
Full-length  ROCK1  remained in the peri-centromeric
region of 18q. This partial duplication corresponds to the
region of ROCK1 (the last for exons and introns) that
included numerous non-uniquely annotated coding
SNPs.
Partial gene duplications commonly produce pseudo-
genes, and we considered whether the partial duplication
of ROCK1 at 18p11.32 represented a ROCK1 pseudogene
[22]. Approximately half of all mammalian protein fami-
lies include pseudogenes http://pseudofam.pseudo-
gene.org, with the greatest representation found in
housekeeping and ribosomal families of genes [23]. While
pseudogenes are commonly considered to be genetic
"fossils" that have no biological function, there are exam-
ples of functional pseudogenes. Expressed pseudogene
transcripts can contribute to the synthesis of small inter-
fering RNA species that regulate parent transcripts
[24,25], and disease-related pseudogenes have also been
reported [26]. A pseudogene can be found for approxi-
mately twenty percent of kinase genes [27,28]; however a
ROCK1 or -2 pseudogene has not been described. The
microtubule-affinity regulating kinase family has the larg-
est number of pseudogenes followed by p70S6 kinase
[27]. Kinase pseudogenes that produce mRNA transcripts
have been identified, but as yet there is no documented
function for these expressed pseudogenes.
Here we report the characterization of the gene pro-
duced by partial duplication of human ROCK1, which we
named  Little ROCK (ROCK1P1). We demonstrate
expression of Little ROCK transcript in human vascular
smooth muscle cells. Despite the high level of nucleotide
identity, we define sequences specific to Little ROCK and
resolve the location of non-synonymous coding polymor-
phisms that were previously reported to be located non-
uniquely within both ROCK1 and Little ROCK.
Results
Little ROCK is a partial duplication of the ROCK1 gene
While researching ROCK1 nucleotide coding polymor-
phisms we noted that dbSNP reported the location of
several potential coding variants in two different parts of
chromosome 18. Indeed, the Ensembl genome browser
reported SNP entries on chromosome 18 both in the
ROCK1  gene (ENSG00000067900) and in the partial
duplication of ROCK1  (ENSG00000215585). For pur-
poses of this report, we call the smaller partial duplica-
tion  Little ROCK. Consistent with its derivation as a
partial duplication and inversion event, Little ROCK
maps to 18p11.32 in the sub-telomeric region, while
ROCK1 is located in the opposite orientation in 18q11.1
near the centromer (Figure 1A). Compared with ROCK1,
which has 33 exons and spans more than 150 kb, the Lit-
tle ROCK gene spans about 13 kb and is predicted to
include 5 exons. We compared the predicted nucleotide
sequences of the two genes and found that the last 4
exons of both genes (exons 2 to 5 of Little ROCK and
exons 30 to 33 for ROCK1) share 99% nucleotide identity.
The predicted first Little ROCK exon is unique and not
Figure 1 Comparison of Little ROCK and ROCK1 genes. (A) Cartoon 
demonstrates location of Little ROCK and ROCK1 on chromosome 18 
and their exon gene structures. (B) The location of the Little ROCK cod-
ing sequence relative to ROCK1 is shown. ROCK1 includes a kinase do-
main and a Rho binding domain (RBD). Little ROCK and ROCK1 share 
pleckstrin homology (PH) and cysteine rich (CRD) domains. The amino 
acid sequence alignment and location of variants reported in dbSNP 
are shown.
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ROCK1     1212  MEPVQQAEKTNFQNHKGHEFIPTLYHFPANCDACAKPLWHVFKPPPALECRRCHVKCHRDHLDKKEDLICPC   1283
Little ROCK  1  MEPVQEAEKTNFQNHKGHEFIPTLYHFPANCDACAKPLWHVFKPPPALECQRRHVKCHRDHLDKKEDLICPC   72
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shared by ROCK1. The Little ROCK mRNA sequence is
predicted to be 2497 bp, while the ROCK1 mRNA mea-
sures 6650 base pairs. Little ROCK transcript includes a
potential initiator methionine residue in exon 2, and the
predicted protein product is 118 amino acids. The pre-
dicted Little ROCK stop codon is located in the exon 4.
Nucleotide BLAST studies did not find any Little ROCK
homologues in other mammalian species, and we did not
detect a duplication of ROCK2 in humans.
Little ROCK transcript is detected in human VSMC and in 
human organs rich in smooth muscle cells
We found a cDNA-derived sequence containing the Little
ROCK-specific sequence including the predicted non-
synonymous coding variants in the nucleotide database
(BC041849). To confirm expression of Little ROCK, we
performed 5' RACE analysis of human VSMC cDNA
using reverse primers that anneal ROCK1 and Little
ROCK. We isolated a total of 9 clones, one of which
included the sequence that matched the Little ROCK-
predicted exon at nucleotide 259 of the mRNA sequence
reported by Ensembl genome browser
(ENST00000400614) (Figure 2A). Having confirmed
expression, we designed RT-PCR assays for analysis of
Little ROCK and ROCK1 transcripts using cDNA
obtained from cell lines and several human organs. We
found the Little ROCK transcript in multiple cultured
vascular smooth muscle cell lines and in testis, stomach,
and vagina (Figure 2B). By comparison, ROCK1  was
expressed in all organs and VSMC lines tested.
Little ROCK has both fixed sequence differences compared 
with ROCK1 as well as non-synonymous polymorphisms
Comparison of the Little ROCK and the ROCK1 nucle-
otide sequences predicted several non-synonymous
sequence variants located at Little ROCK mRNA posi-
tions C526G (rs2847092), A662G (rs1045142), C667T
(rs2663698), and T865C (rs1045144). Because both the
SNP database and the Ensembl Genome Browser could
not resolve whether those variants were located in
ROCK1 or Little ROCK we sought to characterize and to
define the location of these sequence differences. The
high level of intron and exon sequence identity between
Little ROCK and ROCK1 prevented the development of
assays that selectively amplify ROCK1 and Little ROCK
exons from genomic DNA. By comparison, through the
use of forward primers that recognize the Little ROCK
exon 1 sequence or the ROCK1  exon 29 sequence we
were able to specifically amplify the Little ROCK and
ROCK1 cDNA sequences. With these assays we analyzed
and compared amplicon sequence produced from
genomic DNA (Figure 3A) and cDNA (Figure 3B)
C526G (rs2847092) and T865C (rs1045144) are located
in the exon 3 and exon 4 of Little ROCK respectively cor-
responding to exon 31 and 32 of ROCK1. The DNA anal-
ysis of 90 unique human Caucasian DNA samples using a
TaqMan assay for T865C and by direct sequencing of
G526C showed heterozygote genotypes for all samples
analyzed (Figure 3A). Sequence analysis of cDNA synthe-
sized from human VSMC RNA revealed that G526 and
T865 belong to Little ROCK (Figure 3B). From these
Figure 2 Little ROCK Expression Analysis. (A) Nucleotide sequence of a clone isolated by 5'RACE confirmed the Little ROCK transcript includes splic-
ing of sequences with high identity to ROCK1 exon 30 to the Little ROCK-specific Exon 1. Arrowheads indicate exon splice sites. (B) Little ROCK, ROCK1 
and GAPDH amplicons from cDNA produced from Lanes: 1-Testis, 2-Heart, 3-Kidney, 4-Brain, 5- Liver, 6- Lung, 7-Pancreas, 8-Placenta, and 9-Sk. Muscle. 
Lanes 10 to 16 are from cultured human VSMC lines: 10-IM230, 11-Ao146, 12-IM306, 13-Ao297, 14-IM337, 15-Co338, 16-Ao207. Lane 17 shows a neg-
ative control. GAPDH was used as a cDNA loading control.Montefusco et al. BMC Genetics 2010, 11:22
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results we conclude that both these nucleotide "variants"
are actually fixed sequence differences between the
ROCK1 and the Little ROCK genes.
A662G (rs1045142) and C667T (rs2663698) nucleotide
variants are both within the exon 3 of Little ROCK corre-
sponding to exon 31 of ROCK1 gene. The direct sequence
analysis of 90 unique human Caucasian DNA samples
showed polymorphic results where both homozygous GT
and heterozygous GT and AC individuals were repre-
sented within the population. Sequence analysis of the
VSMC ROCK1 cDNA sequence showed exclusively GT
at the two positions (Figure 3B), which indicates that
ROCK1 is not the source of these polymorphisms. By
comparison, the Little ROCK cDNA sequence showed
GT, AC or both. Sequence analysis further demonstrated
that both polymorphisms are in complete linkage dis-
equilibrium, forming two haplotypes: A662-C667 (Hap-
lotype AC) and G662-T667 (Haplotype GT) (Figure 3C).
To confirm the results and to determine the haplotype
frequencies we genotyped the Heart SCORE cohort using
a custom designed TaqMan assay. The frequency of the
Haplotype AC was similar in Heart SCORE African
American and Caucasian participants (minor allele fre-
quency 0.33 versus 0.31, respectively). The two haplo-
types were in Hardy-Weinberg equilibrium (p > 0.05) in
both racial groups.
Little ROCK transcript abundance is reduced compared 
with ROCK1
The custom Little ROCK/ROCK1 TaqMan assay can dis-
criminate the T865C alleles in both genomic DNA and
Figure 3 Analysis of ROCK1/Little Rock nucleotide differences. (A) Chromatograms from amplified genomic DNA that includes both ROCK1 and 
Little ROCK. Gene specific exon amplification was not possible due to high sequence identity. The location of variants identified in dbSNP is shown. 
Overlapping chromatogram peaks with similar sizes indicates locations of sequence variability. (B) Chromatograms from amplified cDNA. The use of 
a primer specific for the Little ROCK-specific exon and a primer specific to ROCK1 ensured the specificity of each amplicon. No ambiguous bases were 
found in the ROCK1 cDNA while rs1045142 and rs2663698 were heterozygous in the Little ROCK cDNA amplicon. (C) The location of fixed sequence 
differences created by ROCK1 and Little ROCK sequence differences (rs2847092 and rs1045144) and Little ROCK Haplotype AC and Haplotype GT cre-
ated by linkage disequilibrium between polymorphisms rs1045142 and rs2663698 are shown. Sequence findings represent the results from 90 unique 
Caucasian DNA samples and from cultured VSMC cDNA analysis.
A)
B)
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Rs1045144
T/C
Little ROCK
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A/G C/T G T
C GT C
C)
4575 CCAGTACAACAAGCTGAAAAAA---CCTAGAGTGTCGAAGATGCCATGTTA---TTCCCCTCGA 4931
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511 CCAGTACAAGAAGCTGAAAAAA---CCTAGAGTGTCAAAGACGCCATGTTA---TTCCCCTTGA 867
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cDNA. Quantitative RT-PCR analysis of four unique
human VSMC lines demonstrated that ROCK1 transcript
had a lower threshold cycle for detection compared with
Little ROCK (Ct mean ± SD 19.26 ± 0.68 versus 22.39 ±
1.29, p < 0.05), which is consistent with higher relative
transcript abundance. By comparison, the ROCK1
threshold cycles were not lower than Little ROCK in anal-
ysis of genomic DNA from the same cell lines. Therefore,
we conclude that while we confirmed expression of Little
ROCK by 5'RACE and RT-PCR, its expression in smooth
muscle cells is reduced compared with ROCK1.
Little ROCK protein is degraded through a proteasome-
dependent pathway
A characteristic feature of pseudogenes is their lack of a
stable protein product [22]. We next tested whether the
Little ROCK protein could be expressed. We cloned
cDNAs encoding Little ROCK-Q51-R53 (Haplotype AC)
or -R51-C53 (Haplotype GT) into expression vectors
fused to a myc-epitope coding sequence. We were unable
to demonstrate expression of N-terminal myc-epitope
t a g g e d  L i t t l e  R OC K  i n  C o s 7  a n d  H e La  c e l l s  ( d a t a  n o t
shown). To provide a more stable chimera, we exchanged
the myc-epitope for enhanced green fluorescent protein
(EGFP) and expressed them in HeLa cells. Little ROCK-
Q51-R53-EGFP and Little ROCK-R51-C53-EGFP fusion
p r o t e i n s  m i g r a t e d  m o r e  s l o w l y  t h a n  E G F P  d u e  t o  t h e
presence of Little ROCK. The increase in size of the
fusion proteins was consistent with the addition of the
predicted size of Little ROCK (13.5 kDa) to EGFP. Nota-
bly, the abundance of the Little ROCK-EGFP fusion pro-
teins was significantly reduced compared with the
c o n t r o l  E G F P  p r o t e i n  ( 9 0 %  l e s s  t h a n  E G F P ) .  W e  n e x t
explored the possibility that Little ROCK is a target of the
ubiquitin proteasome pathway that regulates the levels of
damaged proteins within the cell. Treatment of trans-
fected cells with the proteasome inhibitor MG132 [29]
significantly increased the abundance of the fusion pro-
tein (Figure 4) demonstrating that Little ROCK destabi-
lized EGFP in a proteasome-dependent manner. By
comparison, EGFP was not significantly stabilized by
MG132 suggesting that the effect of proteasome inhibi-
tion on the fusion protein was mediated through effects
from the Little ROCK peptide sequence.
Discussion
Completion of the human genome sequence has identi-
fied numerous chromosome copy number additions and
subtractions that include partial gene duplication. Here
we characterize Little ROCK, created by partial duplica-
tion and translocation of a portion of chromosome 18
immediately following the separation of humans from
great apes [20,21,30]. Pseudogenes are one product of
these duplication events, and several kinase pseudogenes
have been described. We conclude that Little ROCK is a
ROCK1 pseudogene for several reasons. First, despite a
high degree of sequence identity with ROCK1, Little
ROCK includes a disproportionate number of non-syn-
onymous changes in the coding sequence. An excess of
non-synonymous coding changes is characteristic of
pseudogenes, perhaps reflecting a lower level of purifying
selection as the parent gene [31]. Second, pseudogenes
lack regulatory CpG islands in their promoters [22], and
unlike ROCK1 and ROCK2 the first Little ROCK exon is
not preceded by a predicted CpG island. We detected the
Little ROCK transcript in cultured human VSMC, which
is unusual because many pseudogenes are not expressed
[22]. The expression pattern of Little ROCK transcript
was different than ROCK1, a finding that likely reflected
that the ROCK1  upstream gene regulatory promoter
region was not included in the partial duplication event
that created Little ROCK, and because Little ROCK is
located near a telomere [20,21]. Finally, we found the Lit-
tle ROCK protein to be highly unstable and capable of
rendering a stable protein, EGFP, subject to degradation
Figure 4 Little ROCK1 Peptide is Unstable. (A) Western blot of trans-
fected HeLa cells probed with an antibody to GFP. Non-transfected 
control cell lysates are shown in lanes 1 and 2. Transfected cells were 
treated with MG132 (+) or control solvent (-). Expression of EGFP (lanes 
3 and 4) was not affected by MG132 treatment. Cells expressing EGFP-
LR-GT (lanes 5 and 6) and EGFP-LR-AC (lanes 7 and 8) included a slower 
migrating band consistent with the EGFP-Little Rock fusion peptide. 
MG132 treatment increased the abundance of the EGFP-Little ROCK 
fusion peptides. (B) Bar graph demonstrates mean ± SD intensity of 
peptide band normalized to treatment with solvent control. The ex-
periment was performed three times; asterisk indicates the mean in-
tensity of MG132-treated recombinant protein level was significantly 
different (p < 0.05) versus control treatment as determined by t-test 
analysis.Montefusco et al. BMC Genetics 2010, 11:22
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by the ubiquitin-proteasome system. Therefore, despite
evidence of transcript expression, the highly unstable Lit-
tle ROCK peptide is unlikely to accumulate to sufficient
quantities to have a direct functional impact. Therefore,
based upon the unique presence of a partial duplication
of  ROCK1, and the fact that a corresponding ROCK2
duplication was not found, our findings are consistent
with Little ROCK being the sole pseudogene of the ROCK
family of kinases. We have reported our findings to the
HUGO Gene Nomenclature Committee and Little ROCK
has been assigned the symbol: ROCK1P1.
Following completion of the human genome sequence
and analysis of human gene variants it has been estimated
that 12% of the human genome is affected by chromo-
somal gains and losses [32]. Indeed, an emerging problem
is the incomplete annotation of stable chromosomal
duplications and the pseudogenes often contained within
the duplicated regions. Determining the location and
sequence differences associated with chromosomal
duplication is challenging because of the high level of
sequence identity between pseudogenes and their parent
genes. To illustrate this problem we have clarified the
chromosomal location of four variants listed in SNP data-
bases that at the time of preparing this manuscript were
assigned both to ROCK1  and to Little ROCK. Two of
these reported polymorphisms (rs2847092 and
rs1045144) were in fact fixed nucleotide differences that
define Little ROCK compared with ROCK1. By compari-
son we demonstrate two polymorphisms in complete
linkage disequilibrium located exclusively in Little ROCK
(rs1045142 and rs2663698). The polymorphic differences
detected in Heart SCORE participants were found in sim-
ilar allele frequencies in Caucasians and African Ameri-
cans suggesting that the variants were created sometime
after the time of the chromosome 18 event that created
Little ROCK and before divergence of Homo sapiens.
These examples illustrate the need to identify sequence
differences of chromosomal duplications in the ongoing
1,000 Genomes Project.
Pseudogenes are commonly felt to be "junk" DNA, yet
there are examples of pseudogenes that have functional
regulatory effects [33,34]. As an expressed pseudogene,
Little ROCK may also have a direct biological effect, per-
haps affecting VSMC and blood vessel function. The
instability of the Little ROCK fusion protein would sug-
g e s t  t h a t  a n y  f u n c t i o n a l  r o l e  m a y  b e  u n l i k e l y  t o  b e
explained on a peptide level. Future studies will explore
the cross-talk between the Little ROCK and ROCK1
transcripts.
Conclusion
I n  t h i s  r e p o r t  w e  h a v e  c h a r a c t e r i z e d  Little ROCK, an
expressed pseudogene derived from partial duplication of
ROCK1. The large number of pseudogenes in the human
genome creates significant genetic diversity that can have
physiological importance. The finding of genetic variants
distinct to Little ROCK emphasizes the importance of
taking into consideration pseudogenes in all candidate
gene and genome-wide association studies, as well as the
need for complete annotation of human pseudogenome.
Methods
Genomic databases
Human ROCK1 and Little ROCK genomic, mRNA, and
protein sequences were obtained from UCSC genome
browser http://genome.ucsc.edu/cgi-bin/hgGateway and
Ensembl genome browser http://www.ensembl.org/. In
Ensembl genome browser, the identification numbers for
Little ROCK and ROCK1 genes are ENSG00000215585
and ENSG00000067900, respectively.
Little ROCK/ROCK1 DNA and cDNA analysis
Custom oligonucleotide primers designed manually were
synthesized to amplify and sequence the shared Little
ROCK and ROCK1 exons and nearby intron sequences as
well as the cDNA sequences (Table 1). Primers LTEX3F
and LTEX3R were used to amplify exon 3/exon 31 (prod-
uct 437 bp) and primers LTEX4F and LTEX4R amplified
exon 4/exon 32 (product 289 bp). To amplify Little ROCK
and ROCK1 cDNA fragments including the nucleotide
changes of interest, we designed 2 gene specific forward
primers and 1 common reverse primer. The primers used
for Little ROCK cDNA were cDNALTF and cDNACMR;
for ROCK1 cDNA amplification we used cDNARKF and
cDNACMR. The PCR products were obtained following
standard PCR conditions with an initial step at 95° for 10
minutes followed by 40 cycles of three steps at 95° for 30
sec, 57° (exon 3 amplicon) or 60° (exon 4 and cDNAs
amplicons) for 20 sec and 72° for 30 sec. A final step at 72°
for 1 min was added to complete the elongation reac-
tions. The PCR reaction was carried out in a final volume
of 30 μl including 3 μl of cDNA (1/10 of the RT product),
1× polymerase reaction buffer (1.5 mM MgCl2), 0.1 mM
dNTPs, 0.1 μM each primer, and 2 units of AmpliTaq
DNA Polymerase (Applied Biosystems). After purifica-
tion of the PCR product, 125 ng of amplicons and 5
pmoles of primers were used to carry out the sequencing
reaction using Dye Terminator kit (Applied Biosystems,
Foster City, CA).
Human Cohort DNA Studies
The Tufts Medical Center Institutional Review Board
approved these studies. 90 human DNA samples col-
lected from Caucasian patients with cardiovascular dis-
e a s e  w e r e  u s e d  f o r  g e n e  s e q u e n c i n g  s t u d i e s .  H e a r t
Strategies Concentrating on Risk Evaluation (Heart
SCORE) is a single-site prospective community-based
cohort study investigating the mechanisms underlyingMontefusco et al. BMC Genetics 2010, 11:22
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population disparities in cardiovascular disease [35,36].
Our sample included 1,191 individuals (425 African
Americans and 766 Caucasians) who provided consent
and a DNA sample. Observed genotype frequencies were
compared with those expected under Hardy-Weinberg
equilibrium (HWE) using a χ2 test.
TaqMan genotyping assay
Custom TaqMan genotyping assays created for rs1045144
and the haplotype rs1045142/rs2663698 (See Table 1 for
primer and probe sequences) were purchased from
Applied Biosystems (Assays on Demand). The assays
were performed following manufacturing instructions on
a 7900HT real-time PCR system. The reaction volume
was 5 μl and included 10 ng of DNA, 2.5 μl of Universal
PCR master mix (2×) and 0.1 μl of 40× probes. The reac-
tion conditions were: one step at 95° for 10 minutes fol-
lowed by 40 cycles of 15 seconds at 92°C and 1 minute at
60°C. Real time PCR results and genotype calls were
using the SDS 2.3 program (Applied Biosystems).
Expression Analysis in Human Vascular Smooth Muscle Cell 
Lines
Immortalized human VSMC were provided by Dr. Men-
delsohn. Details about explants, isolation, and immortal-
ization of VSMC are reported in Pace MC et. al. [37].
VSMC cultures were maintained at 37°C in 5% CO2
humid atmosphere in a growth medium containing high
glucose DMEM, Fetal Bovine Serum (10%), and Penicil-
lin/Streptomycin (1×). Total RNA was extracted from
VSMC using Trizol solution (Invitrogen, Carlsbad, CA)
following the manufacturer's instructions. 5' RACE
experiments were carried out on human VSMC RNA
with a custom oligonucleotide primer that recognizes
both ROCK1 and Little ROCK transcripts (5RACELT,
Table 1) according to the GeneRacer kit instructions
(Invitrogen). Due to the sequence similarity between
ROCK1 and Little ROCK, one single gene-specific primer
was designed in order to select both Little ROCK and
ROCK1 mRNAs. RT experiments were carried out using
SuperScriptIII enzyme (Invitrogen) on 5 μg of total RNA
Table 1: PCR, sequencing, site-directed mutagenesis primer and TaqMan probe Sequences
Assay Name Sequence
PCR or Sequencing LTEX3F 5'-TTTTAAAGAATCTAAGTCCTAAGCG-3'
LTEX3R 5'-TACACATAAGTTAGTTCATTGAGAC-3'
LTEX4F 5'-CATCAGCAAGAGATATGCTGC-3'
LTEX4R 5'-CCTCTGTGGTGAAAAGCACAA-3'
cDNALTF 5'-TCTCTGCACAGATCACCCAGTAAACTG-3'
cDNARKF 5'-GCTGGAAGAAACAGTATGTTGTGG-3'
cDNACMR 5'-TAGCATCCCACACGATTCCAC-3'
5RACELT 5'-CTTTGGCACAGGCATCACAATTGGC-3'
ROCKF 5'-ATGGTACGATGTGATACAGCG-3'
ROCKR 5'-CTCACTTCCCTGTCAGTAAGG-3'
GAPDHF 5'-GTCGGAGTCAACGGATTTGGT-3'
GAPDHR 5'-GCCATGGGTGGAATCATATTGG-3'
LTGFPF 5'-CCGGAATTCGAACCAGTACAAGAAGCTGAA-3
TaqMan Assay Rs1045144F 5'-TCCACCATCTGGTTTTGTTCGT-3'
Rs1045144R 5'-CGGAAAGACTGATTTGCAGTGGAT-3'
rs1045144-VIC 5'-TTCCCCTTGAACGCT-3'
rs1045144-FAM 5'-CCCCTCGAACGCT-3'
rs1045142/rs2663698F 5'-CCAAACCTCTCTGGCATGTTTT-3'
rs1045142/rs2663698R 5'-CTTTCTTATCTAAGTGATCTCTGTGGCA-3'
rs1045142/rs2663698-VIC 5'-CATGGCATCTTCGACACT-3'
rs1045142/rs2663698-FAM 5'-ATGGCGTCTTTGACACT-3'
Mutagenesis MU2LTR 5'-ACTTAACATGGCATCTTCGACACTCTAGGG-3'
MU2LTF 5'-CCCTAGAGTGTCGAAGATGCCATGTTAAGT-3'Montefusco et al. BMC Genetics 2010, 11:22
http://www.biomedcentral.com/1471-2156/11/22
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extracted from human VSMC. 1/10 of the RT reaction
volume was used for the following PCR. A set of eight
human organ cDNAs were purchased from Clontech
(Clontech, Mountain View, CA). We carried out PCRs for
Little ROCK, ROCK1 and GADPH cDNAs on all cDNA
samples. GAPDH was use as a cDNA loading control.
The  Little ROCK primers were: cDNALTF and
cDNACMR, resulting in a 614 bp PCR product; ROCK1
primers were: ROCKF and ROCKR resulting in a 230 bp
PCR product; and GAPDH primers were: GAPDHF and
GAPDHR, producing a 146 bp PCR product. Primer
sequences are listed in Table 1. The PCR reaction was
carried out in a final volume of 30 μl including 3 μl of
cDNA, 1× polymerase reaction buffer (1.5 mM MgCl2),
0.1 mM dNTPs, 0.1 μM each primer, and 2 units of Ampl-
iTaq DNA Polymerase (Applied Biosystems). Standard
PCR conditions have been used: an initial step at 95° for
10 minutes followed by 35 cycles of three steps at 95° for
30 sec, 60° for 20 sec and 72° for 50 sec. A final step at 72°
for 1 min was added to complete the elongation reac-
tions.
Cloning of Little ROCK cDNA
Little ROCK coding region was cloned into pEGFP-C2
expression vector in order to obtain EGFP-Little ROCK
fusion protein constructs with Little ROCK in frame with
the C-terminus of EGFP. We amplified using cDNALTF
and cDNACMR primers and cloned a fragment of Little
ROCK cDNA, including the entire coding sequence and
part of both the 5' and the 3' UTRs into the pCR4-TOPO
vector (Invitrogen). A clone of Little ROCK was obtained
and we amplified a fragment by using the primers LTG-
FPF (carrying the EcoRI consensus sequence at 5' end)
and M13F that is part of pCR4-TOPO vector sequence
and downstream the EcoRI restriction site. The PCR
product was digested with EcoRI and ligated into the
pEGFP-C2 expression vector at EcoRI cloning sites.
Sequencing reactions confirmed that the nucleotide
sequence of Little ROCK was in frame with EGFP. We iso-
lated the Little ROCK clone showing the A662/C667
nucleotides and we generated the Little ROCK clone car-
rying G662/T667 nucleotides by using the Stratagene
(Stratagene, Cedar Creek, TX) site-directed mutagenesis
quick change mutagenesis kit and primers MU2LTF and
MU2LTR (Table 1). The two clones were respectively
named pEGFP-LRAC and pEGFP-LRGT.
Cell Transfection and Western Blotting
HeLa cells were cultivated in growth medium (10% FBS,
1× Penicillin/streptomycin, DMEM) until 60-80% conflu-
ent. Transfection reactions were carried out with Poly-
Fect reagent (Qiagen, Valencia, CA) using a DNA/
PolyFect ratio of 1 (μg)/10 (μl) following the manufac-
turer's instructions. The cells were washed twice with 1×
PBS 48 hours after transfection and fresh medium con-
taining 10 μM of MG132 or DMSO (same solvent used to
dissolve MG132) as a control was added. The cells were
incubated at 37° for 4 hours. Protein lysates were pre-
pared in lysis buffer (50 mM Tris pH 7.5, 150 mM NaCl,
5% Glycerol, 1% Triton, 10 mM MgCl2, 1 mM EGTA, 1
mM DTT, 25 mM NaF, 20 mM b-Glycerophosphate, 1
mM Na3VO4, 2 mM PMSF, 1× Protein Inhibitors cock-
tail). After protein quantification by BCA protein assay
(Pierce, Rockford, IL), 50 μg of protein lysates were
loaded onto a 12% SDS page. Protein was then transferred
onto a nitrocellulose membrane and then treated with
blocking solution (1× TBST , 5% skim milk). The mouse
anti-GFP antibody (Covance Inc, Princeton NJ, USA),
was diluted 1:2000 in 1× TBST and 2% skim milk. The
secondary Goat anti-mouse HRP conjugated antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) was diluted
1:10000 in 1× TBST and 2% skim milk. ECL plus western
blotting detection system (GE Healthcare, Bukingham-
shire, UK) was used for protein detection. The blotted
membranes were then analyzed on a Typhoon scanner
and the protein band intensity was measured by
ImageQuant TL software (GE Healthcare). Differences in
protein abundance were compared by t-test.
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